Business Context and Reporting Period
This Form 6-K filing by Regentis Biomaterials Ltd. covers the month of December 2025. The report details the closing of the Company's initial public offering (IPO) on December 5, 2025. The Company is a foreign private issuer based in Israel, and its ordinary shares commenced trading on the NYSE American under the symbol "RGNT" on December 4, 2025.
Key Financial Metrics
- Shares Issued: 1,250,000 ordinary shares.
- Offering Price: $8.00 per share.
- Gross Proceeds: Approximately $10 million (before underwriting discounts, commissions, and offering expenses).
- Underwriter: ThinkEquity LLC served as the sole book-running manager.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change reported is the transition from a private entity to a publicly traded company via the successful completion of its IPO. The Company received aggregate gross proceeds of approximately $10 million, representing a significant increase in capital compared to the pre-IPO period. No prior comparable period financial data is provided in this specific filing to assess operational changes.
Guidance, Outlook, and Risks
The filing focuses on the execution of the IPO and does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation of the Underwriting Agreement and press releases. The text does not disclose any unusual items or contingencies related to the offering.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($10 million) are stated.
- Confirm the final listing status and trading volume on the NYSE American under symbol "RGNT".
- Review the full Underwriting Agreement (Exhibit 1.1) for lock-up periods and underwriter options.
- Examine the Company's Form F-1 (File No. 333-285692) for detailed financial statements and risk factors not included in this summary.